Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

被引：0
|
作者：
Hayden L. Bell
Helen J. Blair
Mankaran Singh
Anthony V. Moorman
Olaf Heidenreich
Frederik W. van Delft
John Lunec
Julie A. E. Irving
机构：
[1] Newcastle University Centre for Cancer,Wolfson Childhood Cancer Research Centre, Translation and Clinical Research Institute
[2] ,undefined
[3] Princess Máxima Center for Pediatric Oncology,undefined
[4] Bioscience Institute,undefined
[5] Newcastle University Centre for Cancer,undefined
来源：
Cancer Cell International | / 23卷
关键词：
WEE1; Inhibitors; Leukemia; High-risk; Relapse; Translational; Cell cycle checkpoints;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [21] Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia
    Shukla, Neerav
    Sulis, Maria Luisa
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (09): : 830 - 832
  • [22] The use of idarubicin in combination chemotherapy for high-risk or relapsed childhood acute lymphoblastic leukemia.
    Gu, LJ
    Zhao, HJ
    Chen, J
    Zhen, WM
    BLOOD, 1998, 92 (10) : 216B - 216B
  • [23] Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia
    Rishi S. Kotecha
    Sarah M. Trinder
    Anastasia M. Hughes
    Benjamin H. Mullin
    Sarah Rashid
    Jinbo Yuan
    Jiake Xu
    Owen Duncan
    Patrycja Skut
    Grace-Alyssa Chua
    Sajla Singh
    Joyce Oommen
    Richard B. Lock
    Ursula R. Kees
    Sebastien Malinge
    Vincent Kuek
    Laurence C. Cheung
    Blood Cancer Journal, 15 (1)
  • [24] Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia
    Perova, Tatiana
    Grandal, Ildiko
    Nutter, Lauryl M. J.
    Papp, Eniko
    Matei, Irina R.
    Beyene, Joseph
    Kowalski, Paul E.
    Hitzler, Johann K.
    Minden, Mark D.
    Guidos, Cynthia J.
    Danska, Jayne S.
    SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (236)
  • [25] Therapeutic Complications in a Patient With High-Risk Acute Lymphoblastic Leukemia and Undiagnosed Hereditary Hemochromatosis
    Balagtas, Jay Michael S.
    Dahl, Gary V.
    PEDIATRIC BLOOD & CANCER, 2012, 58 (01) : 101 - 103
  • [26] Triptolide Inhibits MDM2 and Induces Apoptosis in Acute Lymphoblastic Leukemia Cells through a p53-Independent Pathway
    Huang, Mei
    Zhang, Hailong
    Liu, Tao
    Tian, Dan
    Gu, Lubing
    Zhou, Muxiang
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) : 184 - 194
  • [27] Targeting SF3B1 in High-Risk B-Cell Acute Lymphoblastic Leukemia
    Murakami, Yuki
    Konishi, Hiroaki
    Tepper, Cliff
    McPherson, John
    Satake, Noriko
    BLOOD, 2023, 142
  • [28] p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL
    Lee, H. J.
    Gallardo, M.
    Ma, H.
    Zhang, X.
    Larsson, C. A.
    Mejia, A.
    Hornbaker, M. J.
    Qi, Y.
    Su, X.
    Pageon, L. R.
    Quintas-Cardama, A.
    Post, S. M.
    BLOOD CANCER JOURNAL, 2016, 6 : e434 - e434
  • [29] p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL
    H J Lee
    M Gallardo
    H Ma
    X Zhang
    C A Larsson
    A Mejia
    M J Hornbaker
    Y Qi
    X Su
    L R Pageon
    A Quintas-Cardama
    S M Post
    Blood Cancer Journal, 2016, 6 : e434 - e434
  • [30] The multifaceted role of protein kinase CK2 in high-risk acute lymphoblastic leukemia
    Zhou, Yun
    Lian, Haiwei
    Shen, Ning
    Korm, Sovannarith
    Lam, Andrew Kwok Ping
    Layton, Olivia
    Huiting, Leah N.
    Li, Dun
    Miao, Kelly
    Zeng, Aozhuo
    Landesman-Bollag, Esther
    Seldin, David C.
    Fu, Hui
    Hong, Li
    Feng, Hui
    HAEMATOLOGICA, 2021, 106 (05) : 1461 - 1465
12345